Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: A case report [4]

Journal of Clinical Psychiatry

Volumn 68, Issue 4, 2007, Pages 636-637

  Sugiyama, Nobuhiro ^a   Sasayama, Daimei ^a   Amano, Naoji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PAROXETINE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGED; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; LETTER; MAJOR DEPRESSION; NAUSEA; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 34247526330     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0423d     Document Type: Letter

References (7)

1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
2. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629
3. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001;9:393-399
4. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999;55:11-17
5. Jarkova NB, Martenyi F, Masanauskaite D, et al. Mood effect of raloxifene in postmenopausal women. Maturitas 2002;42:71-75
6. Grigoriadis S, Kennedy SH, Srinivisan J, et al. Antidepressant augmentation with raloxifene. J Clin Psychopharmacol 2005;25:96-98
7. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741